Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAST trial of omalizumab before carotid endarterectomy
NL-OMON54785Phase 2Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis and carotid atheroma (CAS) comparing Omalizumab with Placebo (2 arms). Planned start Oct 2023; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
atherosclerosiscarotid atheroma (CAS)
Beyond the preview
Go deeper on NL-OMON54785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54785.